News

Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers
Verastem shows strong late-stage pipeline progress, financial discipline, and a diverse portfolio that support long-term ...
Cancer drug candidate developed using supercomputing and AI blocks tumor growth without toxic side effects
A new cancer drug candidate has demonstrated the ability to block tumor growth without triggering a common and debilitating ...
Labroots5d
Concurrent Inhibition of The RAS Pathway and Autophagy As a Treatment Approach for Pancreatic Cancer - Labroots
Pancreatic ductal adenocarcinoma (PDAC) is characterized clinically by poor survival and mechanistically by KRAS- and autophagy-dependent growth. We and others previously demonstrated that inhibition ...
insideHPC3d
Livermore Lab: Cancer Drug Candidate Developed Using HPC and AI Blocks Tumor Growth
A new cancer drug candidate developed by Lawrence Livermore National Laboratory, BridgeBio Oncology Therapeutics and ...
Mirage News4d
AI-Powered Cancer Drug Halts Tumors, No Toxic Effects
A new cancer drug candidate developed by Lawrence Livermore National Laboratory (LLNL), BBOT (BridgeBio Oncology Therapeutics ...
Stockhead on MSN4d
Prescient advances new therapies for hard-to-treat cancers
CellPryme-M produces superior cells that are more potent and last longer, aiming to double tumour control. CellPryme-A acts ...
HealthDay on MSN5h
Liraglutide May Reduce Migraine Burden in Adults With Obesity, Migraine
For adults with obesity and migraine, liraglutide reduces migraine burden, with reductions in mean monthly headache days and ...
GEN - Genetic Engineering and Biotechnology News5d
Solution Building: Merck Avoids One-Size-Fits-All Approach to AI and ML
Iya Khalil, PhD, discusses Merck & Co.’s approach to artificial intelligence (AI), and success in applying the technology, ...
HotCopper on MSN5d
Prescient Therapeutics CEO highlights PTX-100 progress in RAS-Driven cancer trial
In this HotCopper Capital Compass interview, Prescient Therapeutics (ASX: PTX) CEO James McDonnell discusses the company’s ...
Nature2d
T cells: getting a GRP on Ras - Nature Immunology
Ras proteins were originally identified as oncogenes able to induce cell transformation. Since then they have been shown to regulate distinct signaling pathways and induce the proliferation ...